Eckert & Ziegler Announces Dividend Cut to Fund Future Investments

Eckert & Ziegler, a key player in the radiopharmaceuticals market, has announced a reduction in its dividend to €0.05 per share. This decision, made by the Supervisory Board and Executive Board, aims to allocate more resources towards financing new high-return projects within the radiopharmaceuticals sector, specifically to expand global production capacities. This move is also strategized to decrease reliance on external funding sources.

In a proactive measure, shareholders are to receive an additional share in Pentixapharm AG for each Eckert & Ziegler share they hold, connected to the planned split-off of Pentixapharm AG. This announcement coincides with the report of an 11% increase in sales, totaling €246.1 million for the 2023 financial year. The company also reported a net profit of €26.3 million, equating to €1.26 earnings per share. Looking forward, Eckert & Ziegler forecasts sales to approach €265 million and an EBIT from continuing operations before one-off effects of about €50 million for the 2024 financial year.

The detailed annual financial statements for 2023 are scheduled for release on March 22, 2024, providing a comprehensive overview of the company’s financial health and strategic direction.